At Summer Street Research Partners, our equity research goal – to provide the best healthcare research, ideas, and investment opportunities – seamlessly combines the input of physician consultants with fundamental equity securities analysis. Consequently, we work closely with our clients, keeping their interests in mind and functioning as an intellectual resource in the investment process. To that end, we employ a dedicated team of equity analysts and adjunct staff with unique experiences in the healthcare sector. Their backgrounds range from science to finance and buy-side to sell-side.
Director of Research, Medical Technology
Mark Landy has spent 15 years on Wall Street and in the medical device industry and has significant transactional experience in both the developed and emerging markets. Mr. Landy has been recognized in numerous Institutional Investor Magazine Top Analyst Polls and was named to the “2008 PharmaVOICE 100″ list of the top 100 most inspirational people in the life science industry. Mr. Landy graduated from the University of The Witwatersrand, Johannesburg, South Africa and worked as an oral-facial surgeon in South Africa and the United Kingdom before studying finance and management at the Wharton School of Business.
Ms. Carol Werther
Senior Analyst, Biotechnology
Prior to joining Summer Street Research Partners, Carol Werther worked as a biotechnology consultant for several firms, including Winslow Management and Rx Capital. She has also held senior biotechnology analyst positions at Think Equity and Adams Harkness & Hill. Ms. Werther was recognized by The Wall Street Journal’s “Best on the Street Survey” in 2000 and 2001. She received an MBA from New York University, Stern School of Business, and holds an MS and BS in nutrition sciences from the University of Alabama in Birmingham and Cornell University, respectively.
Ling Wang, CFA
Senior Biotechnology Analyst
firstname.lastname@example.org, (212) 209-3867×1183
Ling Wang, CFA, was previously a senior vice president and senior biotechnology analyst at Brean Murray, Carret & Co. Prior to her work at Brean Murray, Ms. Wang was a research associate covering biotechnology stocks at Rodman & Renshaw from 2006 to 2008. From 2004 to 2006 she was a research assistant in the life science group at Manning & Napier Advisors, Inc., an investment firm with approximately $16 billion in assets under management. Ms. Wang earned her undergraduate degree in biology from Beijing University. She also holds a master’s degree in molecular pharmacology from Albert Einstein College of Medicine and an MBA degree in finance from Yale University.
Bart Classen, M.D.
Chief Scientific Officer
Bart Classen has had experience working in both the pharmaceutical and securities industries. For the majority of years from 1991-2005 Bart was a biopharmaceutical consultant/analyst working with the Perceptive Life Science Fund, Paramount Capital Asset Management, and Prudential Securities. The remainder of Dr. Classen’s time was spent working in the pharmaceutical industry, having started a small biopharmaceutical company in 1991 focused on vaccine and pharmaceutical safety and holding numerous patents on the technology. He received his MD from the University of Maryland, his MBA from Columbia University, and performed a three-year fellowship at NIH.
Prior to joining Summer Street Research Partners, Remi held research assistantships at several institutions, including the Massachusetts Institute of Technology (MIT) and the National University of Singapore (NUS). His research focused on stem cell therapy. Remi holds a MS in mathematics from Ecole Nationale Supérieure d’Arts et Métiers (Paris, France) and a MS in materials science and engineering from MIT.